Study identifier:291
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40 mg bid on the Signs and Symptoms of Chronic Posterior Laryngitis in Patients with Suspected Laryngopharyngeal Reflux
gastrointestinal diseases
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|